FDA's top gene therapy regulator Vijay Kumar leaves his role
The departure of Vijay Kumar from the FDA's Office of Therapeutic Products follows a broader leadership shakeup at the agency and raises questions about continuity in gene therapy oversight.
Vijay Kumar, who led the FDA's Office of Therapeutic Products — the division responsible for regulating cell and gene therapies — has left his post, according to reporting by STAT News. His departure follows a series of leadership changes at the FDA that have affected multiple offices in recent months.
Kumar's office oversees the review and approval of gene therapies, viral vectors, and related biological products, making it one of the most consequential regulatory units for the genomics and rare-disease research community. The timing of his exit — as several high-profile gene therapy applications are at various stages of FDA review — is likely to be watched closely by sponsors, researchers, and patient advocates.
No successor has been publicly named. The FDA has not issued a formal statement on the transition. STAT News, which first reported the departure, describes it as part of a wider pattern of senior-level exits from the agency.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
The senior official responsible for overseeing the approval of gene therapies at the US Food and Drug Administration (FDA) has left his job. Gene therapies are treatments that aim to correct or replace faulty genes causing serious illnesses. The official, Vijay Kumar, led the FDA office that reviews these treatments before they can be offered to patients.
His departure comes after a period of wider staff changes at the FDA. It is not yet clear who will take over his responsibilities. Researchers and patient groups who follow gene therapy developments are watching for updates on how the agency will manage ongoing reviews during this transition.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-06-29STAT+: FDA's top gene therapy regulator is leaving his role